Based on the transcript, Merck's stock is likely to experience a short-term positive impact due to the following factors:

1. **Strong Financial Performance**: Merck reported solid financial results, including revenues of $39.5 billion and non-GAAP EPS of $3.59, which exceeded expectations.

2. **Pipeline and Product Launches**: The company highlighted several promising pipeline catalysts and product launches, including ZEPATIER for hepatitis C and KEYTRUDA for cancer, which are expected to drive growth in 2016.

3. **Cost Management and Shareholder Returns**: Merck demonstrated strong cost management, resulting in significant savings, and returned over $9 billion to shareholders through dividends and share repurchases.

4. **Positive Guidance**: The company provided positive guidance for 2016, expecting low to mid single-digit revenue growth and mid to high single-digit EPS growth, excluding the impact of foreign exchange.

Given these factors, it is likely that Merck's stock will experience a short-term positive impact within the next 1-2 weeks.

Rating: 2